Core Viewpoint - The company plans to issue shares to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd, with a self-inspection period from May 19, 2025, to January 5, 2026 [1] Group 1 - The self-inspection covers the listed company, transaction parties, and related personnel [1] - During the self-inspection, it was found that the company's securities affairs department staff's immediate relative, Xu Chengling, bought and sold 1,400 shares, while the controlling shareholder's director, Zhao Chunxu, bought and sold 7,500 shares [1] - Both individuals claimed not to have used insider information for trading and committed to not trading before the completion of the restructuring [1] Group 2 - The self-inspection and intermediary institution's verification concluded that the trading activities of the relevant parties did not constitute insider trading and do not affect the restructuring [1]
威高血净：发行股份买资产内幕知情人股票买卖自查情况公告